Beyond Air Inc (XAIR) Stock Price, Quote & News

Company Profile

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiol...

Industry: Medical Devices

Sector: Healthcare

Phone: 516 665 8200

Website: www.beyondair.net

Address:

900 Stewart Avenue, Suite 301, Garden City, United States

F_E_Mooch Dec. 26 at 7:07 PM

$XAIR I think we should all have a yard/garage sale and use the proceeds to takeover XAIR. We would probably have money leftover to have a board meeting at a topical location.

0 · Reply

VernCapital Dec. 26 at 5:18 PM

$XAIR New low (again) This has been in tax selling mode for weeks now. Be down in the .50c range next week at this rate. ain’t nobody buying until they can get past wash sale dates

0 · Reply

MavisBeacon Dec. 26 at 4:53 PM

$XAIR uhh

0 · Reply

Say_Whaaaat Dec. 26 at 3:56 PM

$XAIR maybe some solid cancer news moves the needle here. It's so hard watching this go to zero with all the potential

1 · Reply

Dizzier47 Dec. 26 at 3:23 PM

$XAIR years of promise turned into years of disappointment, but now it seems a decent place to buy in

2 · Reply

GreenBuildingG Dec. 25 at 11:17 AM

$XAIR The opportunity set remains meaningful, but only if discipline keeps pace with ambition. The company must show that scale translates into durable margins rather than fragility. Strategic clarity can reduce risk premiums even before growth accelerates. Investors will likely wait for pattern recognition before re‑committing capital.

1 · Reply

DonDon531 Dec. 23 at 6:16 PM

$XAIR hahah

0 · Reply

DonDon531 Dec. 23 at 4:44 PM

$XAIR and scooped up a little more….

0 · Reply

VernCapital Dec. 23 at 4:09 PM

$XAIR Christmas is a time for forgiving and forgetting. Wishing Steve and his team a Merry Christmas!

3 · Reply

DonDon531 Dec. 23 at 4:03 PM

$XAIR bought more @ .87. Don’t know why, I just did…

1 · Reply

Beyond Air® Announces Transition of Chief Financial Officer

Nov 10, 2025, 6:31 PM EST - 6 weeks ago

Beyond Air, Inc. (XAIR) Q2 2026 Earnings Call Transcript

Nov 10, 2025, 4:05 PM EST - 6 weeks ago

Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Sep 22, 2025, 8:00 AM EDT - 3 months ago

Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

Sep 8, 2025, 3:55 PM EDT - 3 months ago

Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds

Sep 3, 2025, 8:00 AM EDT - 4 months ago

Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:00 AM EDT - 4 months ago

Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan

Aug 12, 2025, 7:40 PM EDT - 4 months ago

Beyond Air, Inc. (XAIR) Q1 2026 Earnings Call Transcript

Jul 25, 2025, 8:00 AM EDT - 5 months ago

Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast

Jul 22, 2025, 7:30 AM EDT - 5 months ago

Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.

Jun 17, 2025, 9:53 PM EDT - 6 months ago

Beyond Air, Inc. (XAIR) Q4 2025 Earnings Call Transcript

Jun 17, 2025, 4:32 PM EDT - 6 months ago

Beyond Air Stock Dips After Mixed Q4 Results: Here's What To Know

Jun 17, 2025, 4:01 PM EDT - 6 months ago

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jun 16, 2025, 8:00 AM EDT - 6 months ago

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

Jun 16, 2025, 7:20 AM EDT - 6 months ago

Top Wall Street Forecasters Revamp Beyond Air Expectations Ahead Of Q4 Earnings

May 20, 2025, 8:00 AM EDT - 7 months ago

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

Apr 21, 2025, 4:05 PM EDT - 8 months ago

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

Apr 15, 2025, 4:05 PM EDT - 9 months ago

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

Apr 9, 2025, 4:05 PM EDT - 9 months ago

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

Mar 31, 2025, 8:00 AM EDT - 9 months ago

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

Mar 24, 2025, 4:05 PM EDT - 9 months ago

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

Mar 11, 2025, 7:30 AM EDT - 10 months ago

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

Mar 6, 2025, 4:05 PM EST - 10 months ago

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

Feb 10, 2025, 7:25 PM EST - 11 months ago

Beyond Air, Inc. (XAIR) Q3 2025 Earnings Call Transcript

Feb 10, 2025, 4:05 PM EST - 11 months ago

Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Feb 5, 2025, 9:29 AM EST - 11 months ago

Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 27, 2025, 4:05 PM EST - 11 months ago

Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Jan 24, 2025, 9:15 AM EST - 1 year ago

Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia

Dec 9, 2024, 11:00 AM EST - 1 year ago

National Advertising Division Recommends Beyond Air Discontinue or Modify Comparative Safety Claims for its iNO Products

Dec 3, 2024, 4:05 PM EST - 1 year ago

Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

Dec 2, 2024, 7:30 AM EST - 1 year ago

Beyond Air Receives CE Mark in Europe for the LungFit® PH System

Nov 26, 2024, 7:30 AM EST - 1 year ago

NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board

Nov 14, 2024, 4:05 PM EST - 1 year ago

Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 11, 2024, 7:56 PM EST - 1 year ago

Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript

Nov 11, 2024, 4:05 PM EST - 1 year ago

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2024, 4:22 PM EDT - 1 year ago

Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 2, 2024, 7:30 AM EDT - 1 year ago

Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks

Sep 27, 2024, 7:34 AM EDT - 1 year ago

Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed

Sep 27, 2024, 7:32 AM EDT - 1 year ago

Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital

Sep 27, 2024, 7:30 AM EDT - 1 year ago

Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Jul 31, 2024, 4:15 PM EDT - 1 year ago

Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia

Jul 23, 2024, 4:05 PM EDT - 1 year ago

Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6

Jul 16, 2024, 4:05 PM EDT - 1 year ago

Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024

Jun 24, 2024, 5:48 PM EDT - 1 year ago

Beyond Air, Inc. (XAIR) Q4 2024 Earnings Call Transcript

Jun 24, 2024, 4:15 PM EDT - 1 year ago

Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Jun 24, 2024, 3:32 AM EDT - 1 year ago

Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday

EPAC OMIC ITI STOK

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Beyond Air® Appoints David Webster as Chief Commercial Officer

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)

F_E_Mooch Dec. 26 at 7:07 PM

$XAIR I think we should all have a yard/garage sale and use the proceeds to takeover XAIR. We would probably have money leftover to have a board meeting at a topical location.

0 · Reply

VernCapital Dec. 26 at 5:18 PM

$XAIR New low (again) This has been in tax selling mode for weeks now. Be down in the .50c range next week at this rate. ain’t nobody buying until they can get past wash sale dates

0 · Reply

MavisBeacon Dec. 26 at 4:53 PM

$XAIR uhh

0 · Reply

Say_Whaaaat Dec. 26 at 3:56 PM

$XAIR maybe some solid cancer news moves the needle here. It's so hard watching this go to zero with all the potential

1 · Reply

Dizzier47 Dec. 26 at 3:23 PM

$XAIR years of promise turned into years of disappointment, but now it seems a decent place to buy in

2 · Reply

GreenBuildingG Dec. 25 at 11:17 AM

1 · Reply

DonDon531 Dec. 23 at 6:16 PM

$XAIR hahah

0 · Reply

DonDon531 Dec. 23 at 4:44 PM

$XAIR and scooped up a little more….

0 · Reply

VernCapital Dec. 23 at 4:09 PM

$XAIR Christmas is a time for forgiving and forgetting. Wishing Steve and his team a Merry Christmas!

3 · Reply

DonDon531 Dec. 23 at 4:03 PM

$XAIR bought more @ .87. Don’t know why, I just did…

1 · Reply

Matlow Dec. 23 at 3:34 PM

$XAIR take your losses and run. There is only one way this ending and its in bankruptcy court.

2 · Reply

VernCapital Dec. 23 at 3:25 PM

$XAIR quite literally no buyers

0 · Reply

VernCapital Dec. 22 at 7:35 PM

$XAIR Annual shareholder meeting to held at Olive Garden this year. Free bread sticks

1 · Reply

midnite_clyde Dec. 21 at 11:04 PM

$XAIR Looks like Doug Larson went back to his former employer DBV Technologies. Their stock is up 10 fold this year and they just hit primary end point on a Ph 3 trial for a peanut patch. No, I am not drunk.

1 · Reply

ThatDudeWithNoMoney Dec. 20 at 12:57 AM

Next 2 weeks should get interesting for $ALUR & $XAIR $AZI $MIMI

1 · Reply

MavisBeacon Dec. 19 at 6:16 PM

$XAIR

0 · Reply

VernCapital Dec. 19 at 2:45 PM

$XAIR let’s try this email to Steve.

1 · Reply

BigNik007 Dec. 18 at 9:03 AM

$XAIR Wow, always looking for a ten bagger. But never thought, that I need it to get back to my Buy In...

0 · Reply

good7 Dec. 18 at 3:39 AM

$XAIR XAIR Could Become an Acquisition Target XAIR's patented "cylinder-free" technology is highly attractive to major companies (such as J&J, Medtronic, and Philips). Large companies already have the sales network that XAIR struggles with. If they acquire XAIR, they could start selling its technology to hospitals around the world right away, instantly eliminating XAIR's massive operating losses.

3 · Reply

MavisBeacon Dec. 17 at 5:57 PM

$XAIR nevermind, who am i kidding. This thing is dead. Zero interest

1 · Reply

VernCapital Dec. 17 at 5:46 PM

$XAIR 66k volume 😂 There’s just no buyers even at these levels of 5 cents

0 · Reply

MavisBeacon Dec. 17 at 4:23 PM

$XAIR dead cat bounce, dead cat bounce

0 · Reply

Market Cap	6.03M
Revenue (ttm)	3.71M
Net Income (ttm)	-46.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,256.87%
Debt to Equity Ratio	0.77

Volume	170,100
Avg Vol	565,526
Day's Range	N/A - N/A
Shares Out	8.01M
Stochastic %K	1%
Beta	0.30
Analysts	Strong Sell
Price Target	$8.50